Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 14, 2016BloodOpen Access

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMarco MielcarekUniversity of WashingtonTFTerry FurlongFred Hutch Cancer CenterPOPaul V. O’DonnellMassachusetts General Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mielcarek et al. (2016) studied this question.

synapsesocial.com/papers/6a1068182badbc352afff37fhttps://doi.org/10.1182/blood-2015-10-672071
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide2002 · 493 citations
  2. 2Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial2015 · 109 citations
  3. 3Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning2014 · 284 citations
  4. 4Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria2011 · 697 citations
  5. 5National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report2014 · 5,507 citations